Holen Sie sich die Stockscreener-App
0.315
1.56%
-0.005
Handel nachbörslich:
.32
0.005
+1.59%
Schlusskurs vom Vortag:
$0.32
Offen:
$0.32
24-Stunden-Volumen:
2.14M
Relative Volume:
0.83
Marktkapitalisierung:
$28.41M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.14M
KGV:
-0.1641
EPS:
-1.92
Netto-Cashflow:
$-139.92M
1W Leistung:
+36.90%
1M Leistung:
+21.81%
6M Leistung:
-54.35%
1J Leistung:
-74.39%
1-Tages-Spanne:
$0.3141
$0.3228
1-Wochen-Bereich:
$0.2157
$0.3245
52-Wochen-Spanne:
$0.2157
$1.555
Allakos Inc Stock (ALLK) Company Profile
Firmenname
Allakos Inc
Sektor
Branche
Telefon
650-597-5002
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS, CA
Vergleichen Sie ALLK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALLK
Allakos Inc
|
0.315 | 28.41M | 0 | -166.14M | -139.92M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Allakos Inc Stock (ALLK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-17 | Herabstufung | Jefferies | Buy → Hold |
| 2024-01-16 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-18 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-08 | Fortgesetzt | Jefferies | Buy |
| 2023-09-27 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-05-12 | Hochstufung | Jefferies | Hold → Buy |
| 2023-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2022-09-12 | Herabstufung | SMBC Nikko | Neutral → Underperform |
| 2021-12-22 | Herabstufung | BofA Securities | Buy → Underperform |
| 2021-12-22 | Herabstufung | Cowen | Outperform → Market Perform |
| 2021-12-22 | Herabstufung | Jefferies | Buy → Hold |
| 2021-12-22 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-12-22 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-08-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-15 | Eingeleitet | Cowen | Outperform |
| 2021-05-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-15 | Eingeleitet | BofA Securities | Buy |
| 2020-12-21 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-27 | Eingeleitet | Barclays | Underweight |
| 2020-02-04 | Fortgesetzt | Goldman | Neutral |
| 2018-08-13 | Eingeleitet | Goldman | Neutral |
| 2018-08-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-13 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Allakos Inc Aktie (ALLK) Neueste Nachrichten
Allakos Inc (ALLK) Recovers 48.96% From Low: Are We There Yet? - stocksregister.com
Allakos And 2 Other Promising Penny Stocks To Watch - simplywall.st
Short Interest in Allakos Inc. (NASDAQ:ALLK) Decreases By 13.9% - Defense World
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Allakos Inc.ALLK - PR Newswire
Allakos Inc Inc. (ALLK) Price Performance: A Technical Analysis Perspective - investchronicle.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Allakos, Inc. (ALLK) - TradingView
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Tang Capital’s Concentra nabs a win, making a deal to buy Allakos - Endpoints News
Allakos to be acquired by Concentra Biosciences for 33c per share in cash - TipRanks
ALLK Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Allakos Inc. Is Fair to Shareholders - The Joplin Globe
Allakos Announces Merger Agreement with Concentra Biosciences - TipRanks
Shareholder Alert: The Ademi Firm Investigates Whether Allakos Inc. Is Obtaining a Fair Price for Its Public Shareholders - Bluefield Daily Telegraph
Allakos agrees to Concentra Biosciences acquisition - Investing.com
Allakos stock surges on reverse merger deal (ALLK:NASDAQ) - Seeking Alpha
Allakos to Be Acquired for 33 Cents a Share - MarketWatch
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - The Manila Times
Allakos Inc. Enters Into Agreement To Be Acquired By Concentra Biosciences - MarketScreener
Allakos (ALLK) Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share - StreetInsider
Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in - Bluefield Daily Telegraph
Biotech Deal Alert: Concentra Biosciences Acquires AllakosKey Terms Revealed - Stock Titan
ALLK ALERT: ROSEN, A LEADING FIRM, Reminds Allakos Inc. Investors of Important May 11th Deadline in Securities Class Action First Filed By Firm- ALLK - ACCESS Newswire
Allakos stock plunges to 52-week low of $0.23 amid market challenges By Investing.com - Investing.com South Africa
Allakos stock plunges to 52-week low of $0.23 amid market challenges - Investing.com Australia
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders - Business Wire
Allakos Inc. (NASDAQ:ALLK) Short Interest Update - Defense World
Analyzing Allakos (NASDAQ:ALLK) and Acerus Pharmaceuticals (OTCMKTS:TRLPF) - Defense World
Allakos Inc.: Hold Rating Amid Restructuring and Financial Uncertainty - TipRanks
Allakos faces potential Nasdaq delisting over share price By Investing.com - Investing.com Australia
Allakos Reports Q4 2024 Results Amid Strategic Shift - TipRanks
Allakos faces potential Nasdaq delisting over share price - Investing.com India
Allakos Inc. (ALLK) reports earnings - Quartz
Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results - The Manila Times
Allakos Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Allakos Swings to Surprise Q4 Profit as Major Restructuring Takes Shape - StockTitan
Allakos (ALLK) Projected to Post Quarterly Earnings on Thursday - Defense World
The Curious Case of Allakos - substack.com
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Allakos (ALLK) Investors with Losses to Contact Its Attorneys: 3 DAY APPLICATION DEADLINE ALERT - ACCESS Newswire
Allakos Inc. (ALLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Lee joins Lycia as CMO - BioCentury
It is Poised to be a Bull Market for Allakos Inc (ALLK) - SETE News
Kuehn Law Encourages Investors of Allakos Inc. to Contact Law Firm - EIN News
Introducing Our Rant Against Allakos Inc - US Post News
FY2024 EPS Estimates for Allakos Lowered by Leerink Partnrs - Defense World
Allakos Inc [ALLK] Officer makes an insider purchase of 21,116 shares worth 23219.0. - Knox Daily
This Week’s 14.26% Gain In Allakos Inc (NASDAQ: ALLK) Taught Us Something New - Marketing Sentinel
Evaluating Allakos: Strategic Review, NOL Potential, and Kevin Tang's Activist Stake Amidst Biopharma Challenges - Smartkarma
What To Expect From Eli Lilly’s (LLY) Q4 Earnings - The Globe and Mail
Chronic Spontaneous Urticaria Market Set to Grow Substantially - openPR
Such Is The Power Of Allakos Inc (NASDAQ: ALLK) - Stocks Register
Allakos Inc: -85.21% Growth from 52-Week Low, Yet Analysts Divided - The InvestChronicle
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Allakos Inc - GuruFocus
Finanzdaten der Allakos Inc-Aktie (ALLK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):